Kytopen
kytopen.com
Actively hiring
Biotechnology
Cell & Gene Therapy
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$52.7M
5 rounds on record
Latest round
$7.1M
Venture round · Feb 2025 · 19 mo ago
Team
6
US Form 5500 (plan participants) · Dec 2025 · -54% in a year
Backers
1
Telegraph Hill Partners
The money's age
Due for its next round
19 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
2025
Team shrank to 6 was 13 · US Form 5500 (plan participants)
Apr 28, 2025
Partnership Kytopen Teams Up With Aldevron To Enhance Workflow Solutions For Cell Therapy Developers · Nasdaq
Feb 6, 2025
Raised a round Venture round $7.1M · SEC Form D
Jan 31, 2024
Raised a round Convertible Note $5.7M · SEC Form D
Jan 5, 2023
Board appointment Kytopen Appoints Paul K. Wotton, Ph.D. to Chair of Board of Directors · The Globe and Mail
Sep 27, 2021
Raised a round Series A $32.5M · SEC Form D
Oct 26, 2020
Raised a round Venture round $3.1M · SEC Form D
May 10, 2019
Raised a round Venture round $4.4M · SEC Form D
2017
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Feb 2025 | $7.1M | — | SEC Form D |
| Convertible Note | Jan 2024 | $5.7M | — | SEC Form D |
| Series A | Sep 2021 | $32.5M | — | SEC Form D |
| Venture round | Oct 2020 | $3.1M | — | SEC Form D |
| Venture round | May 2019 | $4.4M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Kytopen Corp. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Paulo GarciaExecutive Officer, DirectorSEC Form D
Julio VegaExecutive OfficerSEC Form D
Michael ChiuDirector, Executive OfficerSEC Form D
Bethany GrantExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Telegraph Hill Partners Similar startupsby what they do, their industry and backers
Waypoint Bio is a biotechnology company pioneering the next generation of cell therapies for solid tumors.
EditCo provides CRISPR gene editing services, CRISPR products & genome engineering solutions for disease models, drug discovery and cell…
Designer cell therapies for pets first and their people next.
OverT is redefining what's possible with programmed, off-the-shelf cell therapies and biologics.
Neurona is developing cell therapies for targeted repair of dysfunctional neural circuits underlying chronic diseases.
Discover GC Therapeutics, a pioneer in scalable, cutting-edge cell therapies designed to revolutionize treatment across a broad range of…
News
Kytopen, T-CURX, and the Fraunhofer IZI Establish Center of Excellence to Develop Advanced, Non-viral Cell Therapies
Kytopen Corp., a leader in non-viral, continuous flow cellular engineering technologies, T-CURX GmbH ("T-CURX"), a leader in transposon-based CAR-T manufacturing, and Fraunhofer IZI, a developer of novel, clinically-relevant cellular therapies, today anno
Read more
Report
Kytopen: Series B Investment To Scale Cell Therapy Manufacturing Platform
Kytopen announced a Series B financing round led by Telegraph Hill Partners, with participation from existing investors, as the company accelerates commercialization of its cellular engineering technology.
Read more
Report
Kytopen and Excellos Explore New Pathways to Non-Viral Cell Therapy Manufacturing
Kytopen Corp., a leader in continuous flow cellular engineering, and Excellos, Inc., a cell therapy CDMO and member of Blood Centers of America (BCA), today announced that the two companies are exploring a collaboration to advance non-viral cell therapy m
Read more
Report
Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow
Kytopen Corp., a leader in providing non-viral, continuous flow cellular engineering technologies and Aldevron, a leading global manufacturer serving organizations in the gene editing, mRNA vaccine and therapeutics, viral gene therapy, and modified gene t
Read more
Report
Kytopen Teams Up With Aldevron To Enhance Workflow Solutions For Cell Therapy Developers
(RTTNews) - Kytopen Corp., and Aldevron, a subsidiary of Danaher Corp. (DHR), Tuesday announced a collaboration to improve the workflow solutions for cell therapy manufacturers, expecting to save time in a cost-effective manner.
Read more
Report
Pro access
Upgrade to see all 10 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
People
Paulo Garcia
Executive Officer, Director
Julio Vega
Executive Officer
Michael Chiu
Director, Executive Officer
Bethany Grant
Executive Officer
Cullen Buie
Director
Ann DeWitt
Director
Adam Wieschhaus
Director
Theresa Tribble
Director
Paxton Major
Director
Edward Freedman
Director
Paul Wotton
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Financials
Total raised
$52.7M
Latest round
Venture - Series Unknown
Funding rounds
5